LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. With over € 2 billion ($2.3 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investors. In 2017, LSP launched LSP HEF 2 with a fund volume of €280 million targeting investment opportunities in private medical technology companies which offer products that can both improve the quality of patient care and lower healthcare spending.
Cardior, Immunic, Orphazyme, Pharvaris, Atlas Genetics, Neuravi, G-Therapeutics, ViCentra...
U3 - 2008 / Jerini - 2008 / Flow Cardia - 2010 / Okairos - 2013 / Sapiens - 2014 / Prosensa - 2015 / Neuravi - 2017
Qiagen - 1996 / Rhein-Biotech - 1999 / Crucell - 2000 / deVGen - 2005 / Movetis - 2010